A phase I, two arm, open-label, randomized, study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in modified release formulations (MR3 and MR4) and compare the bioavailability between MR3, MR4 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects

Trial Profile

A phase I, two arm, open-label, randomized, study to investigate the effect of food on the bioavailability of a single 800 mg imatinib dose in modified release formulations (MR3 and MR4) and compare the bioavailability between MR3, MR4 and imatinib 400 mg twice daily immediate release tablet (IR) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Malignant melanoma; Myelodysplastic syndromes; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 28 Jan 2008 Status change from in progress to completed.
    • 08 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top